Application of an adaptive design to a randomized phase II selection trial in gastric cancer: A report of the study design

Pharmaceutical Statistics

Volumn 5, Issue 2, 2006, Pages 109-118

  Morita, Satoshi ^a   Sakamoto, Junichi ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Adaptive study design; Bayesian trial monitoring; Multiple patient outcomes; Randomized phase II trial

Indexed keywords

FLUOROPYRIMIDINE; FLUOROURACIL; PACLITAXEL;

ADVANCED CANCER; ARTICLE; BAYES THEOREM; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FATIGUE; HUMAN; MATHEMATICAL MODEL; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PROBABILITY; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; SENSITIVITY ANALYSIS; SIMULATION; STOMACH CANCER; TREATMENT OUTCOME; VOMITING;

BAYES THEOREM; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE II AS TOPIC; HUMANS; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; STOMACH NEOPLASMS;

EID: 33745141576     PISSN: 15391604     EISSN: 15391612     Source Type: Journal    
DOI: 10.1002/pst.220     Document Type: Article

References (19)

1. Simon R, Wittes RE, Ellenberg SS. Randomized phase II clinical trials. Cancer Treatment Reports 1985; 69:1375-1381.
2. Lee JJ, Feng L. Randomized phase II designs in cancer clinical trials: current status and future directions. Journal of Clinical Oncology 2005; 23: 4450-4457.
3. Estey EH, Thall PF. New designs for phase 2 clinical trials. Blood 2003; 102:442-448.
4. Thall PF, Simon RM, Estey EH. Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes. Statistics in Medicine 1995; 14:357-379.
5. Thall PF, Sung HG. Some extensions and applications of a Bayesian strategy for monitoring multiple outcomes in clinical trials. Statistics in Medicine 1998; 17:1563-1580.
6. Jennison C, Turnbull BW. Group sequential tests for bivariate response: interim analyses of clinical trials with both efficacy and safety endpoints. Biometrics 1993; 49:741-752.
7. Cook RJ, Farewell VT. Guidelines for monitoring efficacy and toxicity responses in clinical trials. Biometrics 1994; 50:1146-1152.
8. Koizumi W, Kurihara M, Nakano S, Hasegawa K. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. Oncology 2000; 58:191-197.
9. Spiegelhalter DJ, Freedman LS, Parmar MKB. Bayesian approaches to randomized trials. Journal of the Royal Statistical Society, Series A 1994; 157: 357-416.
10. Chaloner K, Rhame FS. Quantifying and documenting prior beliefs in clinical trials. Statistics in Medicine 2001; 20:581-600.
11. Kadane JB, Wolfson LJ. Priors for the design and analysis of clinical trials. In Bayesian biostatistics, Berry DA, Stangl DK (eds). Marcel-Dekker: New York, 1995; pp. 157-184.
12. Garthwaite PH, Kadane JB, O'Hagan A. Statistical methods for eliciting probability distributions. Journal of the American Statistical Association 2005; 100:680-701.
13. Ho CH. Some frequentist properties of a Bayesian method in clinical trials. Biometrical Journal 1991; 33:735-740.
14. Etzioni R, Pepe MS. Monitoring of a pilot toxicity study with two adverse outcomes. Statistics in Medicine 1994; 13:2311-2321.
15. Rosenberger WF, Lachin JM. The use of response-adaptive designs in clinical trials. Controlled Clinical Trials 1993; 14:471-484.
16. Karrison TG, Huo D, Chappell R. A group sequential, response-adaptive design for randomized clinical trials. Controlled Clinical Trials 2003; 24: 506-522.
17. Shimada Y, Shirao K, Ohtsu A, Hyodo I, Saito H, Yamamichi N, Seki S, Ikeda N, Ohashi Y, Yamamoto S, Shimoyama M. Phase III study of UFT + MMC versus 5-FU + CDDP versus 5-FU alone in patients with advanced gastric cancer: JCOG study 9205. The 35th Annual Meeting of American Society of Clinical Oncology 1999; 18: 272a (abstract 1043).
18. Takiuchi H, Goto M, Kawabe S, Ohta S, Katsu K. Second-line chemotherapy in gastric cancer. Gan To Kagaku Ryoho 2005; 32:19-23 (in Japanese).
19. Greenhouse JB, Wasserman L. Robust Bayesian methods for monitoring clinical trials. Statistics in Medicine 1995; 14:1379-1391.